miR-155 has recently emerged as an important promoter of antitumor immunity through its functions in T lymphocytes. However, the impact of T cell expressed miR-155 on immune cell dynamics in solid tumors remains unclear. In the present study, we used single-cell RNA-sequencing to define the CD45+ immune cell populations at different timepoints within B16F10 murine melanoma tumors growing in either wild-type or miR-155 T cell conditional knockout (TCKO) mice. miR-155 was required for optimal T cell activation and reinforced the T cell response at the expense of infiltrating myeloid cells. Further, myeloid cells from tumors growing in TCKO mice were defined by an increase in wound healing genes and a decreased IFN-gamma response gene signature.
Introduction:
MicroRNAs (miRNAs) are short regulatory RNA molecules that inhibit the translation of target messenger RNAs (mRNAs) based on sequence complementarity. Biogenesis of miRNAs involves transcription of miRNA host genes, followed by a series of post-transcriptional processing steps within the nucleus and cytoplasm which result in ~22 nucleotide-long mature miRNA that is loaded into RNA-induced silencing complex (RISC) and capable of target repression (1). Through interacting with multiple targets, miRNAs participate in numerous cellular processes ranging from embryonic development and carcinogenesis to immunity. miR-155 is a classic example of a multifunctional miRNA that plays essential roles in hematopoietic development (2, 3) , inflammatory responses (4) (5) (6) , autoimmunity (7) , and cancer progression (8, 9) . In the context of immunity, miR-155 is upregulated in T cells, B cells, macrophages, and dendritic cells upon cellular activation and it contributes to effector responses by regulating target genes (10) . Recent studies have shown that T cell-specific expression of miR-155 is necessary for optimal antitumor immunity in various experimental models (11) (12) (13) (14) , but a detailed understanding of how T cell expressed miR-155 impacts the tumor microenvironment (TME) is lacking. Further, the impact of miR-155 on the prognosis of human solid tumors remains to be elucidated.
The TME is composed of several different immune cell types with pro-tumorigenic and anti-tumorigenic properties which play an active role in cancer development and progression. Understanding the dynamics of TME is essential for devising effective new cancer therapeutics and predicting which patients are likely to respond to the immunotherapies (15) . The advent of flow cytometry has enabled the characterization of cells infiltrating into the tumor by using cell-specific antibodies, but it is unable to capture the true heterogeneity of the TME and the activation states of infiltrating immune cells. Emerging single-cell RNA sequencing (SCseq) technologies provide a powerful alternative to investigate the characteristics of the TME and study antitumor immune responses at an unprecedented resolution. Recent studies have employed SCseq technology to dissect the molecular features of TME in both preclinical and clinical models and have unveiled the commonalities and context-dependent aspects of antitumor immunity (16, 17) . Expanding the utilization of SCseq to new cancer models will be essential for obtaining a more complete understanding of how the immune system responds to developing tumors with the eventual goal of revealing pathways that can be leveraged for therapeutic purposes.
In this study, we used SCseq to characterize the murine melanoma immune microenvironment in the presence or absence of T-cell specific miR-155 at two different time points. In support of our previous results (11) , miR-155 was found to be essential for antitumor immune responses as evidenced by faster tumor growth in T cell conditional miR-155 knockout mice (miR-155 TCKO). SCseq demonstrated a complex landscape of tumor-infiltrating immune cells including multiple populations of T cells, natural killer (NK) cells, neutrophils, dendritic cells, and macrophages which were defined by distinct activation states in a time-and genotypedependent manner. T cell-specific expression of miR-155 was critical not only for T cell effector responses but also for programming several myeloid cell populations in the TME. Interestingly, analysis of the Cancer Genome Atlas (TCGA) data revealed that miR-155 expression correlates with an improved clinical outcome in human melanoma and defined an immune-enriched tumor subtype. Furthermore, miR-155 expression marked an immune-enriched solid tumor subpopulation across the TCGA solid cancer cohorts and positively correlated with multiple immune signature parameters. We also found that miR-155 expression was associated with an improved clinical outcome, especially in cancers with high mutational burden such as melanoma and lung cancer. Taken together, our results describe the critical role of T cell-specific miR-155 in shaping the TME for effective antitumor immunity. These findings also delineate the characteristics and kinetics of miR-155 mediated antitumor immunity in murine melanoma for the first time and suggest that an antitumor immune response can be defined by miR-155 expression in human cancers.
Results:

SCseq reveals the immune cell diversity within tumor microenvironment in melanoma
The TME is composed of a variety of immune cells which can have both pro-and anti-tumorigenic functions. miR-155 was previously shown to be a critical mediator of antitumor immunity in mice (11) (12) (13) (14) 18) , but the effects of T cell-specific expression of miR-155 on the dynamics of the TME are unknown. To analyze the composition of the TME and the phenotypes of tumor-infiltrating immune cells, we employed 10x Genomics single-cell RNA sequencing (SCseq) technology. B1610 murine melanoma cells expressing chicken ovalbumin (OVA) model antigen were injected subcutaneously into wild-type (WT) and T cell conditional miR-155 knockout (miR-155 TCKO) mice. 9 or 12 days after tumor injection, live CD45+ immune cells were sorted from the pooled tumors (n>4 per time point) via flow cytometry and subjected to SCseq (Figure 1a and S1). Consistent with our previous findings (11), we did not observe a major difference in tumor growth on day 9, whereas on day 12, miR-155 TCKO mice exhibited a higher tumor burden ( Figure 1b ). This suggested a lack of productive antitumor immunity in mice when T cell-specific expression of miR-155 is lost. We aggregated data from 11,054 individual cells (3,624 cells-WT(d9), 1,956 cells-miR-155 TCKO(d9), 1,759 cells-WT(d12), and, 3,715 cells-miR-155 TCKO(d12)) and performed unsupervised clustering analysis based on the similarity of gene expression signatures by using Seurat single cell genomics R package (19) . This analysis revealed 14 distinct cell clusters representative of both lymphoid and myeloid lineages (Figures 1c-d, S2 ).
Due to the high dimensionality of the data and overlapping expression of marker genes, identifying the biological nature of cell clusters from SCseq experiments can be a challenging task (20) . Surveying the expression of known markers can aid in the description of broad immune cell populations ( Figure S2 ), but a more granular analysis of cell clusters requires examining multiple genes simultaneously. To assist with the identification of cell clusters, we developed an algorithm that compares the gene expression signatures of SCseq cell clusters with the publicly available Immunological Genome Project (ImmGen) database (see Methods).
ImmGen database hosts microarray and RNAseq data from more than 200 purified immune cell subsets under various experimental conditions. This algorithm calculates an aggregate identity score for each SCseq cell cluster as a measure of molecular similarity to the ImmGen subsets ( Figure S3 ). With this algorithm, certain cell clusters including plasmacytoid dendritic cells (pDCs), activated and naïve CD8+ T cells, natural killer (NK) cells, and Langerhans cells were confidently identified ( Figures S3, S4 ). For cell clusters in which the algorithm could not make a clear call such as macrophage and neutrophil populations, we resorted to differential expression analysis between clusters to identify distinguishing markers. By combining these two approaches, among 14 distinct clusters in our dataset, we identified three CD8+ T cell subsets (naïve, activated, and activated cycling), one CD4+ T cell subset, three neutrophil/granulocyte subsets (Ly6a+, Cxcl10+, and Arg1+), two macrophage subsets (F4/80-and F4/80+), four DC subsets (Cd209+, Xcr1+, Langerhans, and plasmacytoid), and subsets of NK cells and monocytes (Figure 1c , S5). Differential expression analysis between clusters revealed distinct gene signatures in support of unique molecular characteristics of clusters ( Figure 1d ). Among these clusters, miR-155 host gene (Mir155hg) expression was detected in activated T cells, NK cells, and Langerhans DCs ( Figure 1e ). To verify the algorithm-assisted identification of cell clusters, we examined the expression of known cellular markers in our dataset. As expected, the expression of these markers corresponded with the respective identities of clusters ( Figure 1f ). Not surprisingly, a considerable overlap was observed in the gene expression profiles of closely related cell clusters. These results underscore the need for a multidimensional analytical approach to characterize cellular heterogeneity in the TME and suggest that lymphoid and myeloid cell subpopulations in the TME exhibit distinct molecular characteristics.
Upon confidently identifying cell clusters, we analyzed the differences between WT and miR155-TCKO tumor-infiltrating immune cells on days 9 and 12 after tumor injection. When the data from two time points and genotypes were plotted side-by-side, time-and genotype-dependent dynamics within the TME started to emerge ( Figure 1g ). As early as day 9, the activated CD8+ T cell cluster was enriched in WT samples compared to miR-155 TCKO counterparts, however, on day 12, this difference was much more pronounced (Figure 1g , h). At this later timepoint, the activated T cell cluster was present in miR-155 TCKO mice but was represented at a lower frequency (Figure 1g , gray arrows). A distinct population of activated CD8+ cells characterized by the expression of cell cycle genes (hence named cycling activated CD8+ cluster) was also enriched in WT mice on day 12. Interestingly, activated cycling CD8+ T cell cluster was more pronounced in WT mice on day 12 compared to WT mice on day 9 (Figure 1g , red arrows). NK cells and Xcr1+ DC subset were also enriched in WT samples on day 12, although they looked similar between WT and miR-155 TCKO samples on day 9 (Figure  1g , h). On the contrary, several myeloid populations were expanded in tumors grown in miR-155 TCKO mice by day 12. This was true for all three neutrophil subsets and monocytes in our dataset (Figure 1g , h). The levels of F4/80+ macrophages and pDCs were also elevated, albeit at a lower extent, in miR-155 TCKO tumors on day 12. Taken together, these data suggest that antitumor immune cells expand within the TME between days 9 and 12 of tumor growth in WT mice, whereas, in miR-155 TCKO mice, the TME shifts toward a pro-tumorigenic state in the absence of a productive T-cell response.
T cell-intrinsic miR-155 is essential for antitumor immune activation miR-155 was previously shown to be important for optimal T-cell antitumor responses (6, 11, 12) , but the molecular characteristics of miR-155-competent and -deficient T cell subsets in the TME have not been studied temporally. Next, we focused our analysis on infiltrating T cells to investigate the effects of miR-155 loss on Tcell activation phenotypes. To complement our findings at the cluster level, we first subsetted single-cell gene expression data based on concomitant expression of CD3e and CD8a, as broad markers of cytotoxic T cells. As expected, the loss of miR-155 resulted in lower frequencies of intratumoral CD3+CD8+ T cells at both days 9 and 12 (Figure 2a ). Interestingly, the overall frequency of CD3+CD8+ cells increased in miR-155 TCKO mice from day 9 to day 12, but this increase was attenuated compared to increase in WT mice. When we analyzed interferon gamma (IFNg) expression within these CD3+CD8+ cells, we observed ~2-fold induction in WT mice from day 9 to day 12, while T cells from miR-155 TCKO mice lacked the ability to induce IFNg expression over time ( Figure 2a ). We validated our findings from SCseq by using multicolor flow cytometry and observed lower percentages of CD3+CD8+ T cells and a diminished production of IFNg by these cells in tumors grown in miR-155 TCKO vs WT mice ( Figure 2b) . We then proceeded to analyze the expression levels of known T-cell activation markers and effector molecules within the CD3+CD8+ subset. CD44 and L-selectin (CD62L encoded by Sell gene) are two commonly used markers to distinguish activated (CD44-high, CD62L-low) and naïve (CD44-low, CD62L-high) T cell subsets. Supporting our findings in cluster analysis, we observed higher levels of CD44 and lower levels of CD62L in WT CD3+CD8+ T cells, suggesting an activated phenotype (Figure 2c ).
Both at day 9 and day 12, we observed higher expression levels of IFNg and granzyme B (Gzmb) in WT CD3+CD8+ T cells compared to miR-155 TCKO counterparts, on average ( Figure 2c ). Both IFNg and Gzmb are critical mediators of T cell cytotoxicity against tumors and pathogens (21) . An elevated expression of other activation marker genes such as Pdcd1 (encoding PD-1) and Tnfrsf9 (encoding 4-1BB) were observed in WT T cells, particularly by day 12 of tumor progression. These findings suggest that intratumoral T cell compartment in WT mice is composed of more activated cells compared to miR-155 TCKO mice. In further support to this interpretation, gene set enrichment analysis (GSEA) of CD3+CD8+ intratumoral T cells from WT and miR-155 TCKO mice on day 12 revealed an enrichment for cellular proliferation and effector T cell gene expression signatures for WT samples (Figure 2d ). Further, when we limit the analysis only to the activated T cell cluster (as identified in Figure 1 ), we observed higher expression frequency of multiple activation marker genes including IFNg, GzmB, Pdcd1, and Cd27 (Figure 2e , S6). Taken together, these findings suggest that antitumor T cell responses evolve over time and cell-intrinsic expression of miR-155 is essential for T cells to infiltrate into the tumor and reach an activated state.
Lastly, we wanted to examine the expression levels of miR-155 targets at the single-cell resolution. While the analysis of miRNA targets via commonly used methods such as qPCR, bulk RNAseq, and Western blotting can provide an overall measure from a mixed cell population, delineating the effects of miRNAs in individual cells and studying the heterogeneity of cellular responses to miRNAs are not possible with these methods. For instance, upon experimental manipulation of a miRNA, the target gene expression may be altered uniformly across the population at a certain extent, or it could be altered in a small subset of cells at a much greater level resulting in the same overall observed changes. In this context, SCseq is a novel tool capable of examining the expression of miRNA targets at the individual cell level. Since miR-155 expression is induced in T cells upon activation and floxed miR-155 in our model is deleted only in T cells, we investigated the expression levels of miR-155 targets only in activated T cell clusters within our dataset. We found that these genes were not ubiquitously expressed and had variable expression across the dataset. To address these issues and to show side-by-side results from WT and miR-155 samples with different numbers of T cells, we scaled the frequency of cells to the same relative abundance (the frequency of cells not expressing a gene of interest was normalized to 1, and the relative frequencies of cells expressing the gene is calculated based on this normalized value). As expected, the relative number of cells expressing the target genes were higher in miR-155 TCKO mice at both time points (Figure 2f, g) . Interestingly, the difference between WT and miR-155 TCKO T cells were consistent across the spectrum of target gene expression suggesting a broad de-repression of miR-155 targets as opposed to high levels of upregulation in a narrow subset of T cells upon deletion of miR-155. These results indicate that the expression of miR-155 target genes is similarly affected across single T cell clones supporting the idea that miR-155 expression uniformly modifies target genes within this T cell population in our experimental model.
T cell miR-155 controls the phenotype of tumor-infiltrating myeloid cells
Upon activation, T cells produce several molecules that can interact with myeloid cells and regulate their function (22) . Next, we proceeded to analyze the myeloid cells in tumors grown in WT and miR-155 TCKO mice.
We first examined the frequency of cells expressing Itgam (encoding CD11b) and Adgre1 (encoding F4/80) markers as a measure of macrophages in the TME. We did not observe obvious differences at day 9 between WT and miR-155 TCKO mice, but on day 12, miR-155 TCKO mice had more than 2-fold higher frequency of macrophages compared to WT mice ( Figure 3a) . Interestingly, the levels of intratumoral macrophages in WT mice decreased from day 9 to day 12. When we limit our analysis to CD11b+F4/80-cells as a surrogate for a general myeloid cell phenotype, we also observed a higher proportion in miR-155 TCKO mice on day 12 ( Figure   3a ). Flow cytometry analysis of tumor-infiltrating immune cells validated the observations of SCseq and showed a higher frequency of CD11b+F4/80+ macrophages and CD11b+Gr1+ of myeloid derived suppressor cells (MDSCs) in miR-155 TCKO mice on day 12 (Figure 3b ). CD11b+F4/80+ macrophages in tumors grown in miR-155 TCKO mice expressed higher levels of Arginase 1 (Arg1), tumor growth factor-beta (TGFb1) and chitinaselike 3 (Chil3, also known as Ym1), which are commonly used markers to define pro-tumorigenic M2 state ( Figure   3c ). Changes in the expression levels of Arg1 and Chil3 were validated by qPCR ( Figure S7 ) (23) . Principal component analysis (PCA) of F4/80+ macrophage clusters (as defined in Figure 1 ) using consistently expressed immune associated-genes defined a distinct molecular phenotype for macrophages in miR-155 TCKO mice on day 12 suggesting the myeloid compartment of the TME undergoes phenotypic evolution over time (Figure 3d ).
When the global gene expression signatures of CD11b+F4/80+ macrophages were examined, IFNg response genes were found to be enriched in WT mice, whereas miR-155 TCKO macrophages were enriched for a wound-healing phenotype at both days 9 and 12 (Figure 3e, S8a). Interestingly, when CD11b+F4/80+ cells from WT mice were compared between the two time points, we observed a significant enrichment of IFNg response genes on day 12 ( Figure S8b ), supporting the interpretation that antitumor immune response is enhanced by day 12.
Additionally, the enrichment of an IFNg response signature was evident in several other cell types in the WT tumor microenvironment by day 12 including neutrophils, and various DC populations suggesting IFNg secreted by T cells interacts with multiple cell types in the TME ( Figure S9 ). Complementing our observations with CD11b+F4/80+ macrophages, we also found Arg1 and TGFb1 to be elevated in CD11b+F4/80-cells within the TME of miR-155 TCKO mice ( Figure 3f ). Furthermore, IL-4Ra, a marker MDSCs in both mice and humans (24) was expressed at a higher frequency in CD11b+F4/80-cells of these mice (Figure 3f ), suggesting a greater portion of CD11b+F4/80-cells develop into an MDSC-like phenotype when miR-155 expression is lost in T cells.
These findings demonstrate how tumor infiltrating immune cells in WT mice function together to mount a potent antitumor immune response by day 12 of tumor growth, and show that the loss of miR-155 in T cells reprograms the TME toward a pro-tumorigenic state by affecting multiple myeloid cell subsets.
miR-155 expression defines an immune-enriched subtype of human melanoma
In addition to their roles in immunity, miRNAs were known to be important determinants of tumorigenesis (25) . Specifically, miR-155 was shown to have both pro-tumorigenic (8, 26) and anti-tumorigenic properties (27, 28) depending on the tumor context in a tumor cell-intrinsic manner. Since miR-155 expressed in tumor cells or in infiltrating immune cells can exert different functions, roles of miR-155 in determining tumor prognosis in human cancers remain to be elucidated. Following on our findings in murine B16 melanoma model, we first focused on micro-RNA sequencing (miRNAseq) data from human cutaneous melanoma (SKCM) in TCGA database to assess whether miR-155 expression correlated with survival outcome and clinical parameters.
Expression levels of mature miR-155 across the SKCM patient group were categorized at the top and bottom thirds and Kaplan-Meier survival curves were plotted from miR-155-high and miR-155-low groups with 148 patients each. Our analysis showed that higher expression of miR-155 significantly marks a subpopulation of patients with a favorable clinical outcome in SKCM (Figure 4a ). We then turned to RNAseq data from these patients to investigate the differential gene expression between miR-155-high and miR-155-low groups. Several hundred genes were found to be differentially regulated in miR-155-high melanoma patients (1,784 genes were upregulated, and 206 genes were downregulated >2 fold, with adjusted p-value of <0.05) ( Figure 4b ). PTPRC gene encoding pan-leukocyte marker CD45 was found to be among significantly upregulated genes suggesting an immune enriched subtype in the miR-155-high cohort (Figure 4b , c). Interestingly several genes associated with T cells including T cell receptor complex signal transducers (LCK and LAT), co-receptors (CD4 and CD8A), and effector molecules (IFNG and GZMB) were also upregulated suggesting the presence of activated T cells in the tumor microenvironment ( Figure 4b ). The majority of these genes had more than 4-fold upregulation in miR-
155-high tumors (Figure 4b, c).
A landmark manuscript published by TCGA consortium in 2015 described multiple molecular and clinical characteristics of SKCM (29) . In this manuscript, authors classified melanoma samples into three groups as immune-rich, keratin-rich and MITF-low subclasses depending on the expression of immune-and tumor-specific markers (29) . We next wanted to investigate the clinical classifications and immune-associated gene expression profiles of miR-155-high and miR-155 low tumor subgroups in SKCM. Interestingly, miR-155-high subpopulation of SKCM tumors expressed higher levels of several immune-related genes including general immune cell markers, costimulatory and coinhibitory receptors and effector molecules (Figure 4d ). Of note, mediators of a pro-tumorigenic phenotype such as NOS2 and ARG1 (30) were expressed at slightly higher levels in the miR-155-low group. Strikingly, miR-155-high subpopulation of patients corresponded to immune-rich melanoma subtype as described by the TCGA manuscript (Figure 4d , green column annotations) (29). These findings were further supported by higher lymphocyte infiltration scores in miR-155-high tumors (Figure 4d , dark red column annotations), as described in TCGA study (29) . Interestingly, when we examined the relationship between the expression levels of miR-155 and various immune genes, we noted a strong and nearly linear positive correlation, suggesting the miR-155 expression continuum overlaps with the immune signature in the TME (Figures 4e, S10 ).
miR-155-high human melanoma tumors are highly infiltrated by lymphocytes
Upon observing a positive correlation between miR-155 and immune gene expression, we next performed GSEA in the miR-155-high vs miR-155-low patient cohorts to characterize active signaling networks. In agreement with higher IFNG transcript levels, we observed an enrichment of IFNg response gene signature in miR-155-high tumors (Figure 5a ). Furthermore, miR-155-high melanoma subset was significantly enriched for other inflammatory pathways including tumor necrosis factor alpha (TNFa), interferon alpha (IFNa), and interleukin 2 (IL2) signaling ( Figure S11 ). On the contrary, miR-155-low melanoma subset was characterized by an enrichment in proliferative pathways, indicative of a higher representation of transcripts from tumoral origins in RNAseq data ( Figure S12 ). Of note, miR-155-low subset also exhibited an enrichment of genes regulated by MYC, an oncogene that was shown to negatively regulate antitumor immune responses ( Figure S12 ) (31) .
Understanding which cancer patients will respond to immunotherapy is an important clinical challenge. A recent study examined gene expression profiles of TCGA tumors and defined an "immune signature (IS) score" that predicts responses to various forms of immunotherapy (32) . In this this study, IS score was found to positively correlate with an IFNg response gene signature and tumoral lymphocyte infiltration. Since miR-155 expression also marks an immune-rich subtype in human melanoma, we next wanted to determine the association between IS score and miR-155 expression levels. Our analysis revealed that miR-155 expression is strikingly correlated with IS score in human melanoma (Figure 5b) . Importantly, when the 10 highest and the lowest miR-155-expressing TCGA melanoma samples were examined histologically, a brisk lymphocyte infiltration was evident in miR-155-high subset (Figure 5c, d) . Taken together, these findings further support the role of miR-155 in defining an immune-rich subtype in human melanoma and suggest that intratumoral expression of miR-155 may have important clinical implications.
miR-155 expression positively correlates with immune enrichment in a variety of distinct human solid tumors
The TCGA database currently hosts data from 29 other solid tumor types originating in different tissues (https://cancergenome.nih.gov/). We first surveyed miR-155 expression in TCGA miRNAseq datasets and observed variable levels of expression across different tumor cohorts, SKCM having the highest median miR-clinical outcome in different TCGA cohorts. To this end, we categorized mature miR-155 expression levels in each cancer type by dividing the patient cohort to the top and bottom thirds, as previously done in SKCM, and performed differential expression analysis by using publicly available RNAseq data. To examine the commonalities in differential gene expression among TCGA datasets, we calculated the frequency at which a gene is significantly upregulated in the miR-155-high subsets of TCGA cohorts. In this analysis, if a gene is found to be differentially expressed in the miR-155-high subsets of all TCGA cancers analyzed, the frequency of differential expression would be 100%; whereas, if a gene is significantly upregulated only in half of the TCGA cancers, the frequency would be 50%. By using this approach, we summarized the frequency of differential upregulation for select immune genes in miR-155-high patient subsets (Figure 6b ). As expected, expression of miR-155 host gene (MIR155HG) was elevated in the patient subsets where the mature form of miR-155 was higher ( Figure 6b ). Interestingly, the PTPRC (CD45) gene was found to be upregulated in 96.6% (29/30) of the miR-155-high TCGA tumor cohorts. Furthermore, genes encoding T cell signal transducers and co-receptors such as CD3E, LCK, and CD8A were all upregulated in more than 90% of the time within miR-155-high cancers across the TCGA dataset (Figure 6b . S12). Transcript levels of T cell effector genes such as IFNG, GZMB, PRF1, and TNF were also elevated in at least 50% of these tumors. Of note, multiple other genes encoding canonical markers of immune cell subsets such as KLRB1 (NK1-1; NK cells), ITGAM (CD11B; macrophages and granulocytes), ITGAX (CD11C; dendritic cells), and ADGRE1 (F4/80, macrophages) were also upregulated in miR-155-high cancer subsets (Figure 6b ). To examine functional pathways in these miR-155-high tumor subsets, we performed GSEA by using "GO" and "HALLMARK" gene sets from Molecular Signature Database (MSigDB) (33) , high expression of miR-155 correlated with a strong enrichment of adaptive and innate immune pathways in all solid tumors analyzed regardless of their origin (Figure 6c, S13) . These observations demonstrate that miR-155 expression defines a multicellular immune-enriched phenotype in a wide variety of human solid tumors.
To analyze the immune landscape from a multidimensional point-of-view, we performed PCA with 2,038 genes annotated with "Immune Process" gene ontology (GO) term by using RNAseq data from TCGA solid tumors. Even though the tumor RNAseq data in our analysis originated from several different tissue types, high miR-155 expression designated tumors with a common immune signature distinctly from miR-155-low counterparts as evidenced by the spatial separation of data points in the PCA plot (Figure 6d ). The same trend was observed when PCA was performed with 548 immune-associated genes downloaded from the ImmPort database ( Figure S14a,b) (34) . Not surprisingly, when all the genes in the RNAseq dataset were used in PCA, high miR-155 expression did not define a distinct tumor population ( Figure 6e ) suggesting that miR-155 expression correlates with a consistent immune gene signature rather than describing a difference in global gene expression patterns in human solid tumors. Surprisingly, the level of miR-155 expression was found to correlate positively with the IS score (reported by Ock et al. (32) ) across TCGA solid tumors, mirroring our findings in melanoma ( Figure S15) , further supporting the role of miR-155 in defining a common immune involvement in human cancer.
Lastly, we wanted to investigate the relationship between miR-155 expression in the TME and the survival outcome in human cancers. A univariate Cox proportional hazards model was used to investigate the correlation between miR-155 expression and patient survival data for each TCGA solid tumor cohort. For this analysis, we excluded TCGA tumor types i) that consisted of less than 100 patients or ii) tumors in which a consistent, time-dependent decline in patient survival was lacking (see Figures 6f and S16 for the tumor cohorts included in the analysis). Results of the survival analysis revealed that, although miR-155 expression had a variable relationship with survival depending on the tumor context, it was inversely correlated with the hazard ratio (HR) from Cox survival model (Figure 6f , Table S1 ). In these analyses, HR larger than 1 indicate a poorer survival (i.e. increased hazard), while HR smaller than 1 indicate an improved survival (i.e. decreased hazard or protection). Skin cutaneous melanoma (SKCM) had an HR value of 0.84 corresponding to a 16% decrease in clinical hazard in miR-155-high patient subset (Figure 6f ). Interestingly, when the mutation burden of these TCGA tumors was analyzed, we observed that cancers in which miR-155 correlated with a more favorable clinical outcome (HR<1) tended to have a higher mutational load (Figure 6f , red-colored data points). Among the TCGA cohorts, SKCM exhibited the highest mutational burden followed by lung squamous cell carcinoma (LUSC), where, in both cases, miR-155 expression correlated with an improved prognosis. In summary, miR-155 expression defines an immune-enriched subtype of human cancers and may have an
Discussion
In this study, we described the molecular characteristics of antitumor immune responses mediated by T cellspecific miR-155 at a cellular resolution via single-cell RNA sequencing technology. Our analysis at two different time points revealed distinct activation states of tumor-infiltrating immune cells and delineated the dynamic interactions of these cells within the tumor microenvironment. Supporting the previous literature, loss of miR-155 in T cells was detrimental to antitumor T cell responses (11, 12) . Importantly, T cell-specific expression of miR-155 was also critical for shaping the intratumoral myeloid immune compartment both in terms of cellular composition and activation states. Although miR-155's role in antitumor immunity was evident early during tumor development (day 9), its importance was more pronounced at a later time point (day 12), suggesting a continued evolution of antitumor immune responses. Analysis of TCGA data from human melanoma revealed that miR-155 expression correlates with an immune-enriched subtype and is associated with an improved clinical outcome (29) . Furthermore, analysis of TCGA data revealed that miR-155 expression marked an immune-enriched phenotype in 29 other solid tumor types. Although miR-155 expression did not always correlate with an improved clinical outcome in TCGA tumors, the overall expression level of miR-155 was found to have an inverse relationship with the clinical hazard ratio in a univariate survival analysis. These findings corroborate the roles of miR-155 in promoting antitumor immunity and suggest that miR-155 can be a marker of immune enrichment in human cancers. miR-155 is extensively studied in the contexts of inflammation and carcinogenesis. While miR-155 expression is induced in immune cells upon stimulation (4, 7), cancer cells of various origins frequently overexpress miR-155 (35) . Tumor-intrinsic miR-155 was shown to have both tumor-promoting (3, 8, 26) and tumor-suppressing functions (9, 27) . Although miR-155 largely contributes to inflammatory responses in a variety of immune cell types (4, 7, 13, 18, 36, 37) , it can also promote the function of regulatory T cells which are important negative regulators of the immune response (38) . Therefore, miR-155 expression within the TME can have variable effects on cancer prognosis depending on which cells express miR-155. Our findings here suggest, however, that higher expression of miR-155 in the tumors correlate with an improved survival in human cancer patients. Against the backdrop of renewed interest in miRNA therapeutics, characterization of miR-155-expressing cells within the TME is critical to reveal which populations are dominant and can be targeted for therapeutic purposes.
Previous studies reported that miR-155 is induced in T cells upon activation (7, 12, 36) . In support of these observations, SCseq data in this study revealed significant levels of Mir155hg expression in activated CD8+ T cell clusters which constitute >30% of the tumor-infiltrating immune cells in WT hosts by the 12 th day of tumor growth. Deletion of miR-155 specifically in T cells resulted in lower levels of activated T cells and higher levels of myeloid cells in the TME indicating an inverse relationship between tumor-infiltrating T cells and myeloid cell subsets. Interestingly, when the gene expression landscape of human tumors is examined, both T and myeloid cell-specific genes were frequently co-expressed within the miR-155-high tumor subsets suggesting a broad infiltration of multiple immune cell types. This may be explained by induction and functioning of miR-155 in multiple cell types in the TME. Indeed, miR-155 can be expressed in a variety of immune cells other than activated T cells including macrophages, DCs, NK cells, and B cells (4, 37, 39) . Interestingly, miR-155 was shown to convert immunosuppressive tumor associated DCs to an immunostimulatory phenotype in an ovarian cancer model, suggesting miR-155 axis can be functional in other immune cells in the TME (40) . Albeit in smaller proportions, we detected Mir155hg expression in NK cells and subsets of DCs and macrophages in support of these previous findings. However, due to low sequencing coverage of SCseq, other cells expressing Mir155hg at low levels may be present in our dataset but remain under the detection limit. Similarly, we were unable detect appreciable levels of Ly6G expression in myeloid populations, a marker commonly used in conjunction with CD11b to define MDSCs, although B16 tumors were shown to be rich in MDSCs (41) . Immunomodulatory markers commonly observed in MDSCs were expressed in a considerable portion of CD11b+F4/80-myeloid cells in our dataset which is consistent with the presence of MDSCs in the murine melanoma TME. These findings suggest that a deeper sequencing coverage may be needed to detect genes with low transcript counts in SCseq experiments and underscore the importance of analyzing multiple parameters to define the identity and activation state of cells in the TME.
SCseq technology is increasingly utilized in tumor immunity studies and provides an unprecedented insight into the dynamics of tumor-infiltrating immune cells. By identifying several distinct myeloid and lymphoid cell clusters, our study demonstrates the distinct activation states of immune cells in the murine melanoma TME.
Most of the closely related clusters identified by SCseq through multidimensional analysis of gene expression would have otherwise been characterized as the same cell type via routine immuno-phenotyping methods such as flow cytometry. This emphasizes the importance of high-throughput analyses for the characterization of the cellular heterogeneity within the TME. SCseq in this study also enabled us to assess the expression levels of miR-155 targets in individual cells and describe the genes that are consistently de-repressed in activated T cells upon loss of miR-155 at different timepoints. Therefore, our dataset can serve as a resource to survey known and novel miR-155 targets in the context of an evolving antitumor immune response. In addition to describing an inept T cell phenotype, our study revealed increased levels pDCs, and multiple subsets of neutrophils and macrophages in miR-155 TCKO mice. These cell types were suggested to promote tumor immunoevasion in various experimental settings (42, 43) and will be further investigated in the context of miR-155 dependent antitumor immunity.
Our findings suggest that miR-155 expression may be a general marker of immune infiltration in human cancer. However, since miR-155 can be expressed by both tumor cells and immune cells in the TME, elucidating the cellular origins of miR-155 transcript in bulk RNAseq is challenging. Deconvolution approaches that aim to distinguish gene signatures of cancer and immune cells in RNAseq data can potentially be employed to address this issue and reveal detailed immunobiological characteristics of miR-155-high and -low tumors (44, 45) . Our data showing a strong positive correlation between the expression levels of miR-155 and various immuneassociated genes suggest that miR-155 transcript in bulk tumor RNAseq originates from the immune component. This is further supported by the results of PCA that revealed a consistent immune gene signature within miR-155-high tumor subsets, and by the results of GSEA which showed a significant enrichment of several inflammatory pathways upon high expression of miR-155. Moreover, miR-155-high tumor subsets were characterized by a more predominant immune cell infiltration at the histological level in human melanoma (SKCM). Observing similar trends in both molecular and histological analyses of miR-155-high tumor subsets is intriguing because, while gene expression profiling requires extraction of RNA from a considerably sized tumor tissue, a histological preparation only samples a few micrometers of the tumor. Despite the caveat of subsampling, histological assessment of immune infiltration is a common clinical practice in human melanoma where studies have revealed a positive correlation between intratumoral lymphocyte levels and the clinical prognosis (46) . Our findings suggest that the enhanced immune signature marked by higher expression of miR-155 did not always correlate with an improved clinical outcome across TCGA datasets suggesting that tumorspecific features can play an important role in shaping the antitumor immune response and tumor prognosis.
Two tumor types from TCGA dataset in which miR-155 expression was associated with a better clinical outcome were skin cutaneous melanoma (SKCM) and lung squamous cell carcinoma (LUSC), which are characterized by the highest mutational burden among TCGA cohorts. High genomic instability and mutational burden are thought to generate neoantigens and contribute to tumor immunogenicity (47) . Supporting this notion and findings of this study, previous multivariate analyses of TCGA data revealed that tumor mutational burden correlated with immune infiltration overall, but the clinical outcome was determined by the contribution of other factors including the nature of tumor antigens, and the characteristics of the immune pathways involved (48, 49) .
The central tenet of cancer immunotherapy is not only enhancing immune cell infiltration into tumors but also reprogramming the intratumoral immune landscape for effective tumor killing. By marking an immune-enriched subtype in human cancer, miR-155 expression may identify patients who are likely to benefit from immunotherapies that reprogram the TME for tumor elimination. Indeed, miR-155 expression within TCGA tumors exhibited a remarkable correlation with a previously calculated "immune score" that strongly predicts clinical responses to immunotherapy (32) . In support of miR-155's role in immunotherapeutic responses, our findings in preclinical cancer models revealed that, although the effects of miR-155 loss were largely rescued by immune checkpoint blockade therapy, the optimal responses to immunotherapy required functional miR-155 axis (11) . Therefore, by characterizing the dynamics of miR-155 mediated antitumor immunity and by identifying correlations between miR-155 expression and clinical parameters in human solid cancers, our study opens a new avenue for the pursuit of miR-155 targeting therapeutics and immunotherapy.
Mice miR-155 floxed mice were described previously (5) . To achieve T-cell specific knockout of miR-155, floxed animals were crossed with CD4-Cre mice on the same genetic background. Due to the CD4/CD8 double-positive phase in thymic T cell development, Cre-mediated excision of floxed miR-155 occurs in both helper and cytotoxic T cell subsets (50) . As miR-155 wild-type controls, mice containing floxed miR-155 cassette, but lacking the Cre recombinase were used. 5-10 mice per group were used in the experiments which were repeated at least two times.
Cell culture and tumor experiments
B16F10 murine melanoma cells (ATCC, CRL-7475) or B16F10-OVA cells expressing chicken ovalbumin (OVA) model antigen were used in the tumor experiments (11) . Cells were cultured in DMEM supplemented with 10% fetal bovine serum, penicillin-streptomycin, and L-glutamine. B16F10-OVA cells were provided kindly by Mingnan Chen (University of Utah). To derive B16F10-OVA cells, parental B16F10 cells were transfected with an OVA-expressing plasmid and selected in media containing 0.1mg/ml G418. Cells were passaged at least once prior to injection and were 80-90% confluent on the day of injection. Adherent cells were trypsinized and washed 3 times in PBS and adjusted to 1x10 6 cells per 100 μl injection volume in PBS. Cells were injected into shaved flanks of mice under isoflurane anesthesia. Tumor growth was monitored throughout the experimental duration of 9-12 days. At the experimental endpoints of day 9 and day 12 following tumor injection, tumors were collected for flow cytometric analysis and single-cell RNA sequencing respectively.
SCseq and analysis
Sample preparation and sequencing
Tumor tissues were dissociated by the help of scissors and forceps and incubated in 5 ml Accumax (Innovative Cell Technologies) with constant agitation at room temperature for 30 minutes. Tumor from at least for single-cell RNA sequencing (SCseq) via 10X platform according to the manufacturer's instructions. 125 cycle paired-end RNA sequencing was performed via Agilent HiSeq next-generation sequencer. Sequencing reads were processed by using 10X Genomics CellRanger pipeline and further analyzed with Seurat R package. The effect of mitochondrial gene representation and the variance of unique molecular identifier (UMI) counts were regressed out from the dataset prior to analysis. Gene expression signatures defining cell clusters were analyzed after aggregating 4 samples (WT and miR-155 TCKO, days 9 and 12). The raw data from SCseq experiments in this manuscript can be found in the Gene Expression Omnibus (GEO) database with "GSE121478" accession number.
Identification of cell clusters
Cells in our dataset was clustered by using "FindClusters" function of the Seurat analysis package which identifies clusters via a shared nearest neighbor (SNN) modularity optimization-based algorithm. This function identified 14 distinct clusters spanning the lymphoid and myeloid cell lineages. We noted that CD4+ T cells were clustered with a larger cell cluster composing mainly of CD8+ T cells. To increase the granularity of our analysis, we manually separated this cluster and named it accordingly, resulting in the 15 clusters analyzed throughout the manuscript. The biological identity of cell clusters were annotated by the help of an immune-cell scoring algorithm (developed in-house and available at: http://labs.path.utah.edu/oconnell/resources.htm) and by surveying known immune cell markers in the SCseq dataset. The immune-scoring algorithm compares the gene signatures of the cell clusters in this study with the publicly available microarray data hosted in the Immunological Genome Project Database (ImmGen). By using differentially expressed gene signatures from Seurat, immunescoring algorithm performs the following steps: 1) For each ImmGen cell population, and for each gene found in ImmGen microarrays, it calculates the ratio of normalized microarray signal to the average signal value of the gene from the whole ImmGen data 2) Applies natural log-transformation to the ratio resulting in positive numbers for upregulated genes and negative numbers for downregulated genes in ImmGen datasets 3) Multiplies ImmGen log-ratio values with the log-ratio of matching genes that are differentially expressed in each cell cluster in the SCseq dataset 4) Sums up scores from all the genes to yield an aggregate identity score for each ImmGen cell type for a given SCseq cluster. In this approach, genes that are differentially upregulated or downregulated in both ImmGen and scSeq datasets contribute to the immune identity score more heavily (a positive number is obtained when two log-ratio values with the same sign are multiplied). On the contrary, if a gene is inversely regulated in ImmGen and SCseq clusters, immune identity score is reduced. Through this methodology, the correlation between the gene expression signatures of SCseq cell clusters in our study and ImmGen data subsets assists in determining the cluster identities. In cases where this algorithm is unable to make a clear call (as in myeloid cell subsets), we surveyed the expression of known genes in the dataset and performed differential expression analyses between closely related cell clusters. This approach allowed us to further differentiate subsets of neutrophils, macrophages and T cell clusters. Upon naming the clusters, Seurat R package was used to create plots for the expression of selected genes. GSEA analysis was performed by using fgsea R package (51) , after ranking genes using signal-to-noise metric (52) .
Flow cytometry
For the staining of tumor infiltrating immune cells, tumor tissue was mechanically disrupted and incubated for 30 mins at room temperature in 5 ml Accumax (Innovative Cell Technologies). Following incubation, cells were filtered through 0.45-micro nylon filter to obtain single cell suspensions. Cells were stained in Hank's balanced salt solution (HBSS) supplemented with 0.5% BSA and 2mM EDTA by using the following fluorophore- 
Analysis of TCGA data
Categorization of miR-155 expression and survival analysis
Publicly available TCGA data were downloaded using TCGABiolinks and RTCGA R packages (53, 54) .
Reads-per-million miRNA counts from miRNA sequencing experiments were used for the categorization of miR-155 expression levels in cancer patients. Glioblastoma tumors (TCGA-GBM) were excluded from analysis due to the lack of miRNAseq. In the remaining solid tumor cohorts, data only from primary tumors were considered for all tumor types except cutaneous melanoma (TCGA-SKCM). For SKCM, both metastatic and primary tumor samples were analyzed since the majority of the samples were derived from metastatic tumors. In rare cases where both primary and metastatic tumor data are available from the same patient, only the primary tumor data were included in the analyses. For each type of tumor, hsa-mir-155 expression was categorized at the top and bottom thirds quantiles (67 th and 33 rd percentile), and patient subpopulations were termed as miR-155-high and miR-155-low based on these cutoffs. Survival analysis was performed by using survival and survminer R packages. Survival outcome in miR-155-high vs miR-155-low patient subpopulations was examined by using Kaplan-Meier, log-likelihood statistics and univariate Cox proportional hazards model. For this analysis tumor cohorts with at least 100 patients that exhibit a gradual time dependent decline in survival were included.
RNA-sequencing differential expression analysis
Raw count data from miR-155-high and miR-155-low patient subpopulations were downloaded by using TCGABiolinks R package. For differential expression analysis, limma R package was used which tests differential gene expression between samples by using a linear model (55) . RNAseq data were normalized via voom transformation as part of this package for each tumor type separately after removing lowly expressed genes. Differentially expressed genes were visualized in volcano and bar plots.
Gene Set Enrichment Analysis (GSEA)
Voom-transformed RNAseq expression values from miR-155-high and miR-155-low patient subpopulations were ranked by using signal-to-noise metric (52) . Ranked gene lists were then analyzed for gene set enrichment by using fgsea R package (51) . Gene sets used in these analyses were derived from the Molecular Signature Database (MSigDB) (33) and previously published manuscripts that investigated immune signatures in various tumor contexts.
Principal Component Analysis (PCA)
PCA was used to investigate the relationship between miR-155-high and miR-155-low patient subpopulations of the TCGA dataset. After limiting the analysis to the shared genes between tumor types, either the whole expression dataset or only the immune-related genes were used for PCA. For these analyses, lists containing ~1000 immune-specific genes were downloaded from the ImmPort database (34) or from the Gene Ontology browser .
Tumor histology and the assessment of immune infiltration miRNAseq data from the TCGA database was analyzed and the 10 highest and 10 lowest miR-155 expressing tumors were selected for histological examination in each solid tumor cohort. H&E stained frozen tumor sections were assessed for immune infiltration by using TCGA data repository web interface (https://portal.gdc.cancer.gov/repository). For this analysis, biospecimen IDs were randomized and provided to a board-certified anatomic pathologist (A.H.G.), who was blinded to the miR-155 expression levels. Tumor sections devoid of immune cells were scored with (-). Tumors were scored (+) if a non-brisk localized lymphocyte infiltrate is observed. (++) score was given if a brisk and widespread lymphocyte infiltration is present across the tumor tissue.
Statistics
Assessments of tumor growth and flow cytometry data were performed using two-tailed Student's T-tests.
Wilcoxon test was used for analyzing gene expression in select SCseq clusters. Reported p-values were corrected for multiple comparisons by Holm-Sidak method (ns: >0.05, *: p ≤0.05, **: p ≤0.01, ***: p ≤0.001, ****: p ≤0.0001). P-values less than 0.05 were considered statistically significant throughout the manuscript. P-value from logrank test was reported in SKCM survival graph. In TCGA differential expression analyses, Benjamini-Hochberg corrected p-values calculated by limma R package are plotted.
Study Approval
All experimental procedures and handling of mice were performed in accordance with the Institutional Animal Care and Use Committee (IACUC) regulations and approved protocols. TCGA data analyzed in this manuscript are publicly available via National Cancer Institute Genomic Data Commons (GDC) and do not require regulated approval. showing elevated levels of CD8+ T cells in tumors of WT mice, and higher levels of IFNg production by these cells. Two-tailed T test was used for statistical comparisons, ns: p>0.05, *: p ≤0.05. C. Expression levels of T cells activation markers and effector genes within the CD3+CD8+ cells are shown. Sell, Pdcd1, and Tnfrsf9 encode for CD62L, PD-1, and 4-1BB respectively. In these plots, each dot represents a single cell. Normalized expression values were used, and random noise was added to show the distribution of data points. The box plot shows interquartile range and the median value (bold horizontal bar). Average expression value per sample is indicated by the red points. Wilcoxon test was used for statistical comparisons (ns: p>0.05, *: p ≤0.05, **: p ≤0.01, ***: p ≤0.001, ****: p ≤0.0001). D. Gene set enrichment analysis (GSEA) of CD3+CD8+ cells in SCseq data on day 12. Normalized enrichment score (NES) and adjusted p-value are shown. WT CD8+ T cells were enriched for cell cycle genes and genes upregulated in effector CD8+ T cells (gene sets were derived from MSigDB) (33) . E. Analysis of activation markers within activated CD8+ T cell cluster (as defined in Figure 1) showing a more robust activation phenotype in WT T cells. F. Analysis of the miR-155 target gene expression in activated CD8+ T cell clusters on day 9. The x-axis of the stacked histograms indicates the normalized expression values of target genes and the y-axis indicates the scaled frequency of cells. To account for differences in cell numbers per sample, the frequency of cells with no expression of the indicated genes was scaled to 1. Dashed lines indicate the average expression values in each group. G. Analysis of miR-155 targets in activated CD8+ T cell clusters on day 12. Data were scaled similarly to panel G. 
